alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Third District Court of Appeal

State of Florida 

Opinion filed March 30, 2022.

Not final until disposition of timely filed motion for rehearing.

________________

No. 3D21-0716

Lower Tribunal No. 12-13148 SP

________________

United Automobile Insurance Company,

Appellant,

vs.

Millennium Radiology, LLC, 

d/b/a Millennium Open MRI, 

a/a/o Ali Leonardo,

Appellee.

An Appeal from the County Court for Miami-Dade County, Chiaka 

Ihekwaba, Judge.

Michael J. Neimand, for appellant.

Marks & Fleischer P.A., and Gary Marks (Ft. Lauderdale); David B. 

Pakula, P.A., and David B. Pakula (Pembroke Pines), for appellee.

Before SCALES, LINDSEY, and MILLER, JJ. 

PER CURIAM.
2

Appellant United Automobile Insurance Company appeals from a final 

summary judgment entered in favor of Appellee Millennium Radiology, LLC. 

The trial court concluded that United Automobile was collaterally estopped 

from challenging the reasonableness of the cost of MRI procedures that 

Millennium performed. For the reasons set forth in United Automobile 

Insurance Co. v. Millennium Radiology, LLC, 47 Fla. L. Weekly D175 (Fla. 

3d DCA Jan. 12, 2022), which addressed the same issue, we reverse.1

Reversed and remanded.

1 We recognize that the trial court did not have the benefit of this recent 

decision.
Editorial Note on Part 73
Editorial Note: Nomenclature changes to part 73 appear at 66 FR 66742, Dec. 27, 2001.

§ 73.1015 Chromium-cobalt-aluminum oxide. ( a ) *Identity.* The color additive chromium-cobalt-aluminum oxide is a blue-green pigment obtained by calcining a mixture of chromium oxide, cobalt carbonate, and aluminum oxide. It may contain small amounts (less than 1 percent each) of oxides of barium, boron, silicon, and nickel.
( b ) *Specifications.* Chromium-cobalt-aluminum oxide shall conform to the following specifications: Chromium, calculated as Cr2 O3, 34-37 percent. Cobalt, calculated as CoO, 29-34 percent. Aluminum, calculated as AL2 O3, 29-35 percent. Lead (as Pb), not more than 30 parts per million. Arsenic (as As), not more than 3 parts per million. Total oxides of aluminum, chromium, and cobalt not less than 97 percent.
Lead and arsenic shall be determined in the solution obtained by boiling 10 grams of the chromium-cobalt-aluminum oxide for 15 minutes in 50 milliliters of 0.5 *N* hydrochloric acid.
( c ) *Uses and restrictions.* The color additive chromium-cobalt-aluminum oxide may be safely used for coloring linear polyethylene surgical sutures, United States Pharmacopeia (U.S.P.), for use in general surgery, subject to the following restrictions: ( 1 ) For coloring procedure, the color additive is blended with the polyethylene resin. The mixture is heated to a temperature of 500-550 °F. and extruded through a fixed orifice. The filaments are cooled, oriented by drawing, and set by annealing.
( 2 ) The quantity of the color additive does not exceed 2 percent by weight of the suture material.
( 3 ) The dyed suture shall conform in all respects to the requirements of the U.S.P. XX (1980).
( 4 ) When the sutures are used for the purpose specified in their labeling, there is no migration of the color additive to the surrounding tissue.
( 5 ) If the suture is a new drug, an approved new drug application, pursuant to section 505 of the Federal Food, Drug, and Cosmetic Act, is in effect for it.
( d ) *Labeling.* The label of the color additive shall conform to the requirements of § 70.25 of this chapter.
( e ) *Exemption from certification.* Certification of this color additive is not necessary for the protection of the public health, and batches thereof are exempt from the certification requirements of section 721(c) of the act.
[42 FR 15643, Mar. 22, 1977, as amended at 49 FR 10089, Mar. 19, 1984]
<TABLE> <S> <C>

<PAGE>
 
<ARTICLE> 5
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          MAR-31-1997
<PERIOD-END>                               DEC-29-1996
<CASH>                                          39,921
<SECURITIES>                                         0
<RECEIVABLES>                                  723,605
<ALLOWANCES>                                    42,573
<INVENTORY>                                    524,673
<CURRENT-ASSETS>                             1,287,067
<PP&E>                                         825,100
<DEPRECIATION>                                 278,547
<TOTAL-ASSETS>                               2,618,774
<CURRENT-LIABILITIES>                          608,504
<BONDS>                                      1,308,203
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           209
<OTHER-SE>                                     443,676
<TOTAL-LIABILITY-AND-EQUITY>                 2,618,774
<SALES>                                      1,820,967
<TOTAL-REVENUES>                             1,802,967
<CGS>                                        1,369,083
<TOTAL-COSTS>                                1,369,083
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                   842
<INTEREST-EXPENSE>                              92,251
<INCOME-PRETAX>                                 49,194
<INCOME-TAX>                                    23,259
<INCOME-CONTINUING>                             26,777
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    26,777
<EPS-PRIMARY>                                     1.29
<EPS-DILUTED>                                        0
        

</TABLE>
Exhibit 32.1



CERTIFICATION PURSUANT TO 18 U.S. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002, each of the undersigned officers of GlycoGenesys, Inc. (the Company), hereby certifies, to his knowledge, that:



(1) the Companys annual report on Form 10-K for the year ended December 31, 2004(the
Report) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and



(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company as of and for the periods presented in the Report.



Dated: March
30, 2005



|    |  |                                                 |  |  |  |     |  |                                              
|--- |  | ----------------------------------------------- |  |  |  | --- |  | ---------------------------------------------
|By: |  | /S/    JOHN W.
BURNS                            |  |  |  | By: |  | /S/    BRADLEY J CARVER                      
|    |  | Name: John W. Burns Title: SVP, CFO & Secretary |  |  |  |     |  | Name: Bradley J Carver Title: CEO & President
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 13-2224

ORLANDO BROWN,

Plaintiff - Appellant,

v.

RICHLAND COUNTY SHERIFF’S DEPARTMENT,

Defendant - Appellee.

Appeal from the United States District Court for the District of 

South Carolina, at Columbia. Margaret B. Seymour, Senior 

District Judge. (3:12-cv-03062-MBS)

Submitted: January 23, 2014 Decided: January 27, 2014

Before WILKINSON and DIAZ, Circuit Judges, and HAMILTON, Senior 

Circuit Judge.

Affirmed by unpublished per curiam opinion.

Orlando Brown, Appellant Pro Se. Robert David Garfield, Andrew 

Lindemann, DAVIDSON & LINDEMANN, PA, Columbia, South Carolina, 

for Appellee.

Unpublished opinions are not binding precedent in this circuit.
2

PER CURIAM:

Orlando Brown appeals the district court’s order 

accepting the recommendation of the magistrate judge and denying 

relief on his 42 U.S.C. § 1983 (2006) complaint. We have 

reviewed the record and find no reversible error. Accordingly, 

we affirm for the reasons stated by the district court. 

Brown v. Richland Cnty. Sheriff’s Dep’t, No. 3:12-cv-03062-MBS 

(D.S.C. Sept. 13, 2013). We dispense with oral argument because 

the facts and legal contentions are adequately presented in the 

materials before this court and argument would not aid the 

decisional process.

AFFIRMED
###### Editorial Note on Part 316

#### Editorial Note:

Nomenclature changes to part 316 appear at 69 FR 13717, Mar. 24, 2004.

#### § 316.22 Permanent-resident agent for foreign sponsor.

Every foreign sponsor that seeks orphan-drug designation shall name a permanent resident of the United States as the sponsor's agent upon whom service of all processes, notices, orders, decisions, requirements, and other communications may be made on behalf of the sponsor. Notifications of changes in such agents or changes of address of agents should preferably be provided in advance, but not later than 60 days after the effective date of such changes. The permanent-resident agent may be an individual, firm, or domestic corporation and may represent any number of sponsors. The name of the permanent-resident agent, address, telephone number, and email address shall be provided to: Office of Orphan Products Development, Food and Drug Administration, Bldg. 32, rm. 5271, 10903 New Hampshire Ave., Silver Spring, MD 20993.

[78 FR 35133, June 12, 2013]
§ 601.20 Biologics licenses; issuance and conditions. ( a ) *Examination—compliance with requirements.* A biologics license application shall be approved only upon examination of the product and upon a determination that the product complies with the standards established in the biologics license application and the requirements prescribed in the regulations in this chapter including but not limited to the good manufacturing practice requirements set forth in parts 210, 211, 600, 606, and 820 of this chapter.
( b ) *Availability of product.* No biologics license shall be issued unless: ( 1 ) The product intended for introduction into interstate commerce is available for examination, and
( 2 ) Such product is available for inspection during all phases of manufacture.
( c ) *Manufacturing process—impairment of assurances.* No product shall be licensed if any part of the process of or relating to the manufacture of such product, in the judgment of the Director, Center for Biologics Evaluation and Research or the Director, Center for Drug Evaluation and Research, would impair the assurances of continued safety, purity, and potency as provided by the regulations contained in this chapter.
( d ) *Inspection—compliance with requirements.* A biologics license shall be issued or a biologics license application approved only after inspection of the establishment(s) listed in the biologics license application and upon a determination that the establishment(s) complies with the standards established in the biologics license application and the requirements prescribed in applicable regulations.
( e ) *One biologics license to cover all locations.* One biologics license shall be issued to cover all locations meeting the establishment standards identified in the approved biologics license application and each location shall be subject to inspection by FDA officials.
[64 FR 56451, Oct. 20, 1999, as amended at 70 FR 14983, Mar. 24, 2005]
§ 520.2345a Tetracycline capsules. ( a ) *Specifications.* Each capsule contains 50, 100, 125, 250, or 500 milligrams (mg) tetracycline hydrochloride.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Conditions of use in dogs* — ( 1 ) *Amount.* 25 mg per pound of body weight per day in divided doses every 6 hours.
( 2 ) *Indications for use.* For treatment of infections caused by organisms sensitive to tetracycline hydrochloride, such as bacterial gastroenteritis due to *E.* *coli* and urinary tract infections due to *Staphylococcus* spp. and *E. coli.*
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[70 FR 50182, Aug. 26, 2005, as amended at 73 FR 18442, Apr. 4, 2008; 79 FR 28831, May 20, 2014]
Exhibit 23.2

INDEPENDENT AUDITORS' CONSENT

We  consent  to the  incorporation  by  reference  in this  Amendment  No.  1 to
Registration  Statement No. 333-69238 of PSEG Energy Holdings Inc. of our report
dated March 23, 2001,  and to the reference to us unde the heading  "Experts" in
such Prospectus, which is a part of this Registration Statement.

October 1, 2001
# C_2016027EN.01000201.xml

| 25.1.2016 | EN | Official Journal of the European Union | C 27/2 |
| --- | --- | --- | --- |

25.1.2016

EN

Official Journal of the European Union

C 27/2

---

Request for a preliminary ruling from the Corte Suprema di cassazione (Italy) lodged on 21 February 2014 — Agenzia delle Entrate v Aquapur Multiservizi SpA

(Case C-307/14)

(2016/C 027/02)

Language of the case: Italian

Referring court

Referring court

Corte Suprema di cassazione

Parties to the main proceedings

Parties to the main proceedings

Applicant: Agenzia delle Entrate

Applicant:

Defendant: Aquapur Multiservizi SpA

Defendant:

Questions referred

Questions referred

By order of 18 November 2015 the President of the Court has ordered that the case be removed from the register.

---
### Geology and ground-water resources of Prowers County, Colorado

By: Paul T. VoegeliLloyd A. Hershey

                            https://doi.org/10.3133/wsp1772

#### Links

- More information:  **National Geologic Map Database Index Page**                            (html)
-                                                                                                                             Document:                                                                                                                                                                                                                                                  **Report**                                                                                                     (pdf)                                                                                                                                     
- Plates:                               - **Plate 1**                            (pdf)
  - **Plate 2**                            (pdf)
  - **Plate 3**                            (pdf)
  - **Plate 4**                            (pdf)
  - **Plate 5**                            (pdf)
  - **Plate 6**                            (pdf) 
- Download citation as:  RIS                         |                         Dublin                            Core

#### Abstract

Part or all of this report is presented in Portable Document Format                        (PDF). For best results viewing and printing PDF documents, it is recommended that you download                        the documents to your computer and open them with Adobe Reader. PDF documents opened from your                        browser may not display or print as intended. Download the latest version of Adobe Reader, free of charge. More information                        about viewing, downloading, and printing report files can be found at the common download problems FAQ.
Exhibit 32.1Certification Pursuant to Rule 13a-14(b) of the Securities Exchange Act of 1934     In connection with the quarterly report on Form 10-Q of Youbet.com, Inc. (the “Company”) forthe period ended September 30, 2005, as filed with the Securities and Exchange Commission as of thedate hereof (the “Report”), I, Charles F. Champion, Chief Executive Officer of the Company, and I,Gary W. Sproule, Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C.Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:     (1) the Report fully complies with the requirements of Section 13(a) of the SecuritiesExchange Act of 1934, as amended; and     (2) the information contained in the Report fairly presents, in all material respects, thefinancial condition and results of operations of the Company.        November 9, 2005 By:  /s/ Charles F. Champion    Charles F. Champion    President and Chief Executive Officer      November 9, 2005 By:  /s/ Gary W. Sproule    Gary W. Sproule    Chief Financial Officer and Treasurer   A signed original of this written statement required by Section 906, or other documentationauthenticating, acknowledging, or otherwise adopting the signature that appears in typed formwithin the electronic version of this written statement required by Section 906, has been providedto Youbet.com, Inc. and will be retained by Youbet.com, Inc. and furnished to the Securities andExchange Commission or its staff upon request.This certification “accompanies” the Quarterly Report on Form 10-Q to which it relates, is notdeemed filed with the Securities and Exchange Commission, and is not to be incorporated byreference into any filing of the Company under the Securities Act of 1933, as amended, or theSecurities Exchange Act of 1934, as amended (whether made before or after the date of the QuarterlyReport on Form 10-Q, irrespective of an general incorporation language contained in such filing).
§ 349.78 Labeling of eyewash drug products. ( a ) *Statement of identity.* The labeling of the product identifies the product with one or more of the following terms: “eyewash,” “eye irrigation,” or “eye irrigating solution.”
( b ) *Indications.* The labeling of the product states, under the heading “Indications,” one of the following phrases: ( 1 ) “For” (select one of the following: “flushing,” “irrigating,” “cleansing,” “washing,” or “bathing”) “the eye to remove” (select one or more of the following: “loose foreign material,” “air pollutants (smog or pollen),” or “chlorinated water”).
( 2 ) “For” (select one of the following: “flushing,” “irrigating,” “cleansing,” “washing,” or “bathing”) “the eye to help relieve” (select one or more of the following: “irritation,” “discomfort,” “burning,” “stinging,” “smarting,” or “itching”) “by removing” (select one or more of the following: “loose foreign material,” “air pollutants (smog or pollen),” or “chlorinated water”).
( c ) *Warnings.* In addition to the warnings in § 349.50, the labeling of the product contains the following warnings under the heading “Warnings” for all eyewash products: ( 1 ) “If you experience eye pain, changes in vision, continued redness or irritation of the eye, or if the condition worsens or persists, consult a doctor.”
( 2 ) “Obtain immediate medical treatment for all open wounds in or near the eyes.”
( 3 ) “If solution changes color or becomes cloudy, do not use.”
( d ) *Directions.* The labeling of the product contains the following information under the heading “Directions”: ( 1 ) *For eyewash products intended for use with an eyecup.* Rinse cup with clean water immediately before each use. Avoid contamination of rim and inside surfaces of cup. Fill cup half full and apply the cup to the affected eye, pressing tightly to prevent the escape of the liquid, and tilt the head backward. Open eyelids wide and rotate eyeball to ensure thorough bathing with the wash or lotion. Rinse cup with clean water after each use.
( 2 ) *For eyewash products intended for use with a nozzle applicator.* Flush the affected eye as needed, controlling the rate of flow of solution by pressure on the bottle.
[53 FR 7090, Mar. 4, 1988, as amended at 68 FR 7921, Feb. 19, 2003]
Editorial Note on Part 60
Editorial Note: Nomenclature changes to part 60 appear at 68 FR 24879, May 9, 2003, and at 88 FR 45065, July 14, 2023.

§ 60.1 Scope. ( a ) This part sets forth procedures and requirements for the Food and Drug Administration's review of applications for the extension of the term of certain patents under 35 U.S.C. 156. Patent term restoration is available for certain patents related to drug products (as defined in 35 U.S.C. 156(f)(2)), and to medical devices, food additives, or color additives subject to regulation under the Federal Food, Drug, and Cosmetic Act or the Public Health Service Act. Food and Drug Administration actions in this area include: ( 1 ) Assisting the United States Patent and Trademark Office in determining eligibility for patent term restoration;
( 2 ) Determining the length of a product's regulatory review period;
( 3 ) If petitioned, reviewing and ruling on due diligence challenges to the Food and Drug Administration's regulatory review period determinations; and
( 4 ) Conducting hearings to review initial Food and Drug Administration findings on due diligence challenges.
( b ) References in this part to the Code of Federal Regulations are to chapter I of title 21, unless otherwise noted.
[53 FR 7305, Mar. 7, 1988, as amended at 57 FR 56261, Nov. 27, 1992]
Fourth Court of Appeals

San Antonio, Texas

JUDGMENT

No. 04-24-00403-CV

Lydia MARTINEZ,

Appellant

v.

33 REAL CONSTRUCTION LLC,

Appellee

From the County Court at Law No. 2, Webb County, Texas

Trial Court No. 2024CVD000002L2

Honorable Victor Villarreal, Judge Presiding

BEFORE JUSTICE CHAPA, JUSTICE RIOS, AND JUSTICE WATKINS

In accordance with this court’s opinion of this date, this appeal is DISMISSED FOR 

WANT OF PROSECUTION. We order all costs of this appeal to be taxed against appellant.

SIGNED August 21, 2024.

_________________________________

Luz Elena D. Chapa, Justice
#### § 203.1 Scope.

This part sets forth procedures and requirements pertaining to the reimportation and wholesale distribution of prescription drugs, including both bulk drug substances and finished dosage forms; the sale, purchase, or trade of (or the offer to sell, purchase, or trade) prescription drugs, including bulk drug substances, that were purchased by hospitals or health care entities, or donated to charitable organizations; and the distribution of prescription drug samples. Blood and blood components intended for transfusion are excluded from the restrictions in and the requirements of the Prescription Drug Marketing Act of 1987 and the Prescription Drug Amendments of 1992.
<PAGE>   1
                                                                     Exhibit 8.1


                              LIST OF SUBSIDIARIES

<TABLE>
<CAPTION>
DIRECT SUBSIDIARIES                                           COUNTRY OF FORMATION
<S>                                                           <C>
Nera America Latina Ltda                                      Brazil
Nera Americas Holding Inc.                                    USA
Nera de Mexico SA De CV                                       Mexico
Nera Electronics AS                                           Norway
Nera Finans AS                                                Norway
Nera GmbH                                                     Germany
Nera (HK) Ltd.                                                Hong Kong
Nera (India) Ltd.                                             India
Nera Ltd.                                                     United Kingdom
Nera Networks AS                                              Norway
Nera Satcom AS                                                Norway
Nera Wireless Broadband Access AS                             Norway

<CAPTION>
INDIRECT SUBSIDIARIES                                         COUNTRY OF FORMATION
<S>                                                           <C>
Beijing Nera Stentofon Comm. Co. Ltd.                         China
Nera Americas Inc.                                            USA
Nera America Latina Inc.                                      Colombia
Nera Mechatronics AS                                          Norway
Nera Networks Inc.                                            USA
Nera Telecomm Ltd.                                            Singapore
Nera Telecommunications Inc.                                  USA
United Marine Electronics Ltd.                                Jersey
</TABLE>